Diabetes Mellitus: A Risk Factor Affecting Visual Outcome in Branch Retinal Vein Occlusion

Swart, Jack de; Reichert-Thoen, J. W.; Suttorp-Schulten, Maria S. A.; Rens, Ger Hmb van; Polak, B.C.P.

doi:10.1177/112067210301300709

Cited by 7 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, largestudiesusing hospital-basedcontrols have shown an increased risk of RVOinpatients with hypertension, diabetes mellitus, atherosclerosis and hypercholesterolemia (6)(7)(8)(9)(10)(11)(12)(13)(14).Literature on associated thrombophilic abnormalitiesin varioustypes of RVOhas accumulated over the years,predominantlybased on retrospectiveretrievalofinformation from case records of variable numbers of patients seen in routine clinical practice ( 15). Prospective studieso nt his subjecth owever are rare.…”

Section: Introductionmentioning

confidence: 99%

Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?

Janssen¹,

Heijer²,

Cruysberg³

et al. 2005

Thromb Haemost

221

View full text Add to dashboard Cite

Previous studies have shown an increased risk of retinal vein occlusion (RVO) in patients with hypertension, hypercholesterolemia and diabetes mellitus. Literature on the association between thrombophilic factors and RVO consists of small studies and case reports. The objective was to determine the relationship between thrombophilic risk factors and RVO. Thrombophilic risk factors analyzed were hyperhomocysteinemia, MTHFR gene mutation, factor V Leiden mutation, protein C and S deficiency, antithrombin deficiency, prothrombin gene mutation, anticardiolipin antibodies and lupus anticoagulant. For all currently known thrombophilic risk factors odds ratios for RVO were calculated as estimates of relative risk. The odds ratios were 8.9 (95% CI 5.7 - 13.7) for hyperhomocysteinemia, 3.9 (95% CI 2.3 - 6.7) for anticardiolipin antibodies, 1.2 (95% CI 0.9 - 1.6) for MTHFR, 1.5 (95% CI 1.0 - 2.2) for factor V Leiden mutation and 1.6 (95% CI 0.8 - 3.2) for prothrombin gene mutation. In conclusion, regarding thrombophilic risk factors and RVO there is only evidence for an association with hyperhomocysteinemia and anticardiolipin antibodies, factors that are known as risk factors for venous thrombosis as well as for arterial vascular disease. The minor effect of factor V Leiden mutation and the protrombin gene mutation (risk factors for venous thrombosis only) suggests that atherosclerosis might be an important factor in the development of CRVO.

show abstract

Section: Introductionmentioning

confidence: 99%

Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?

Janssen¹,

Heijer²,

Cruysberg³

et al. 2005

Thromb Haemost

221

View full text Add to dashboard Cite

show abstract

“…4,5,22 However, Swart et al observed that BRVO patients having diabetes had a worse visual acuity as compared to patients without diabetes. 23 Fifteen out of 40 (37.5 %) patients had diabetes in the current study. Salomon et al showed hyperlipidemia as a risk factor for BRVO.…”

Section: Discussionmentioning

confidence: 58%

Risk factors and Response of Branch Retinal Vein Occlusion induced Macular Edema to intravitreal injections of Triamcinolone and Bevacizumab

Singhai¹

2016

DJO

View full text Add to dashboard Cite

Background: Branch retinal vein occlusion (BRVO) is a common retinal vascular condition associated with systemic risk factors like hypertension and diabetes mellitus. It causes central visual loss primarily due to macular edema that responds to intravitreal injections of triamcinolone and bevacizumab. Aims: To find the risk factors and compare the effects of intravitreal injections of triamcinolone and bevacizumab in BRVO induced macular edema. Settings and Design: A tertiary eye center based prospective, interventional study. Materials and Methods: Patients of BRVO were evaluated for substance abuse and systemic vascular diseases. 40 eyes of 40 patients of BRVO received intravitreal injections of triamcinolone acetonide (IVTA, 4 mg/0.1 ml, 20 patients) or bevacizumab (IVB, 1.25 mg/0.1 ml, 20 patients) for macular edema. The patients were followed for 12 months. Best-corrected visual acuity and central macular thickness by optical coherence tomography were measured to assess the response to treatment. Statistical Analysis: Statistical package for the social sciences (SPSS) version 20.0 software was used to analyze the data. Wilcoxon signed rank test was performed to see the improvement in logMAR visual acuity after the treatment. Results: Hypertension was the commonest risk factor. Tobacco addiction, diabetes mellitus, hyperhomocyteinemia and dyslipidemia were other systemic associations of BRVO. Both IVTA and IVB were effective in reducing the macular edema and improving the vision at the end of 12-month follow-up period. Conclusion: Hypertension and tobacco use in various forms are important risk factors for BRVO. Both IVTA and IVB show comparable response to macular edema secondary to BRVO.

show abstract

“…It is noteworthy that our findings of worse visual outcome have been corroborated in a small study reporting a mean VA of 20/63 in 28 diabetic eyes compared with 20/40 in 49 nondiabetic eyes at 1 and 2 years, although the primary treatment modality was grid-pattern laser. 14 In our study, the number of injections that diabetic eyes required at 1 year is slightly higher than anti-VEGF treat-asneeded regimens for ranibizumab and bevacizumab. In a review of 21 eyes with BRVO on a treat-as-needed protocol with intravitreal ranibizumab, the average baseline VA was 20/72.…”

Section: Brvo Outcomes In Diabeticsmentioning

confidence: 52%

The Effect of Select Systemic Medications on Visual Outcomes in Diabetics With Branch Retinal Vein Occlusion

Birnbaum¹,

Thomas

et al. 2019

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

Purpose: The purpose of this article is to evaluate the effect of systemic medications and glycemic control on the visual outcome and treatment burden in patients with diabetes and branch retinal vein occlusion (BRVO). Methods: A retrospective review was performed for patients with diabetes diagnosed with a BRVO at an academic eye center from 2009 to 2017. The use of select antihypertensives, antiplatelet agents, anticoagulants, and hypoglycemics was reviewed. Data on visual acuity (VA), central subfield thickness (CST), treatment course, and hemoglobin (Hb)A1c were obtained throughout follow-up. Results: A total of 121 eyes met criteria with a median follow-up duration of 19.4 months. The mean baseline logarithm of the minimum angle of resolution (logMAR) VA was 0.56 (Snellen equivalent, 20/72) and mean final logMAR VA was 0.5 (20/63). At final follow-up, aspirin 325 mg was associated with 4.8 fewer injections (n = 13, P = .04), insulin was associated with 3.6 more injections (n = 26, P = .04), warfarin was associated with a 79 µm increase in CST ( P = .02), and a 1% increase in HbA1c was associated with 0.86 more injections ( P < .01). Conclusions: The VA outcome of BRVO in diabetics may be worse than that of BRVO in nondiabetics. Worse diabetic control was associated with a higher treatment burden. High-dose aspirin was associated with fewer injections.

show abstract

Diabetes Mellitus: A Risk Factor Affecting Visual Outcome in Branch Retinal Vein Occlusion

Abstract: The VA 1 year after BRVO in patients with diabetes is worse compared to the VA in patients without diabetes. The VA stabilizes 1 year after onset in both groups. Diabetic patients tend to need more frequent follow-up in order to treat the sequelae of BRVO.

Cited by 7 publications

References 9 publications

Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?

Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?

Risk factors and Response of Branch Retinal Vein Occlusion induced Macular Edema to intravitreal injections of Triamcinolone and Bevacizumab

The Effect of Select Systemic Medications on Visual Outcomes in Diabetics With Branch Retinal Vein Occlusion

Contact Info

Product

Resources

About